Altasciences acquires Sinclair Research and continues to expand pre-clinical platform
Altasciences has announced its acquisition of Sinclair Research, a pre-clinical CRO, to expand its services across the US.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Altasciences has announced its acquisition of Sinclair Research, a pre-clinical CRO, to expand its services across the US.
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
Taking a novel approach to antibiotic discovery, researchers at Rockefeller University have hit upon a promising solution to the problem of superbugs – a pervasive threat in hospitals the world over.
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
With a range of tools available to scientists in the field of therapeutic discovery and development, flow cytometry presents an advantageous method to sort cells based on subtle differences. To find out more, Drug Target Review’s Victoria Rees spoke with Dr Peter O’Toole, Head of Imaging and Cytometry and Dr…
Researchers have found a quinoxaline-core containing, non-genotoxic lead compound that could treat schistosomiasis following optimisation.
This ebook includes articles on flow cytometry in drug discovery and how it is applied to leishmaniasis research. Also included is a piece on how flow cytometry is being used to support the translational research of immuno-oncology therapies.
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
Transformational machine learning (TML) learns from multiple problems and improves performance while it learns, potentially accelerating drug discovery.
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
A new computer-aided tool maps allosteric sites in G protein-coupled receptors to search for allosteric drugs to treat a range of diseases.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.